NCT06742333View on ClinicalTrials.gov

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

October 1, 2028

Conditions
Psoriasis
Interventions
DRUG

Bimekizumab

Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12

DRUG

Clobetasol

Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks

Trial Locations (7)

13005

NOT_YET_RECRUITING

Hôpital Saint-Joseph, Marseille

13500

NOT_YET_RECRUITING

Cabinet Dermatologie Dr RUER, Martigues

42055

RECRUITING

CHU Saint-Etienne, Saint-Etienne

69003

NOT_YET_RECRUITING

Hôpital Edouard Herriot, Lyon

69100

NOT_YET_RECRUITING

Médipole Villeurbanne, Villeurbanne

83000

NOT_YET_RECRUITING

HIA Saint-Anne, Toulon

06200

RECRUITING

CHU de Nice - Hôpital de l'Archet, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT06742333 - Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? | Biotech Hunter | Biotech Hunter